Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

Oussalah, Abderrahim; Babouri, Abdenour; Chevaux, Jean–Baptiste; Stancu, L.; Trouilloud, Isabelle; Bensenane, Mouni; Boucekkine, T.; Bigard, Marc‐André; Peyrin–Biroulet, Laurent

doi:10.1111/j.1365-2036.2008.03902.x

Cited by 36 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some possible explanations may include the following: (1) RA patients may be more immobile and therefore have greater difficulty in attending hospital and therefore would be happier to self-administer at home; (2) Adalimumab has been licensed for a longer period of time in RA, and these patients may have more experience or knowledge of its use than IBD patients; and (3) many Rheumatology Units have dedicated Rheumatology nurses available to administer these biological drugs, and to instruct and counsel patients. This scenario of provision of specialist nurses is not the reality in many IBD units in the UK as evidenced by the UK Inflammatory Bowel Disease Audit in 2006 which highlighted the inadequate provision of dedicated IBD nurses [23]. Rheumatology patients may feel that they have better contact with the medical and/or nursing team if required and therefore may be better educated and prepared to self-administer anti-TNF drugs at home.…”

Section: Discussionmentioning

confidence: 99%

How do patients with inflammatory bowel disease want their biological therapy administered?

2010

View full text Add to dashboard Cite

BackgroundInfliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-TNF drugs appear to be equally efficacious in the treatment of Crohn's Disease and therefore the decision regarding which drug to choose will depend to some extent on patient choice, which may be based on the mode of administration.The aims of this study were to compare preferences in Inflammatory Bowel Disease (IBD) patients for two currently available anti-TNF agents and the reasons for their choices.MethodsAn anonymous questionnaire was distributed to IBD patients who had attended the Gastroenterology service (Ulster Hospital, Dundonald, Belfast, N. Ireland. UK) between January 2007 and December 2007. The patients were asked in a hypothetical situation if the following administering methods of anti-TNF drugs (intravenous or subcutaneous) were available, which drug route of administration would they choose.ResultsOne hundred and twenty-five patients fulfilled the inclusion criteria and were issued questionnaires, of these 78 questionnaires were returned (62 percent response). The mean age of respondent was 44 years. Of the total number of respondents, 33 patients (42 percent) preferred infliximab and 19 patients (24 percent) preferred adalimumab (p = 0.07). Twenty-six patients (33 percent) did not indicate a preference for either biological therapy and were not included in the final analysis. The commonest reason cited for those who chose infliximab (iv) was: "I do not like the idea of self-injecting," (67 percent). For those patients who preferred adalimumab (sc) the commonest reason cited was: "I prefer the convenience of injecting at home," (79 percent). Of those patients who had previously been treated with an anti-TNF therapy (n = 10, all infliximab) six patients stated that they would prefer infliximab if given the choice in the future (p = 0.75).ConclusionsThere was a trend towards patient preference for infliximab (iv) treatment as opposed to adalimumab (sc) in patients with IBD. This difference may be due to the frequency of administration, mode of administration or differing 'times in the market-place', as infliximab had been approved for a longer period of time in Crohn's disease. Further studies are required in IBD patients to investigate whether patient choice will affect compliance, patient satisfaction and efficacy of treatment with anti-TNF therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

How do patients with inflammatory bowel disease want their biological therapy administered?

2010

View full text Add to dashboard Cite

show abstract

“…In a small study, a higher percentage of patients were previously reported to require an adalimumab dose increase (nearly 60% at 6 months) after using a suboptimal induction regimen of 80/40 mg [12]. In another 2 cohorts, only 13.2 and 29% of patients required a dose increase [14,15]. …”

Section: Discussionmentioning

confidence: 99%

“…Patients with CD seen in daily practice may differ from the selected patients included in randomized trials [12,13,14,15]. In a multicenter open-label single-arm study (CARE), adalimumab therapy showed substantial efficacy at week 4 (43% remission rate), which was sustained through week 20 (52% remission rate), including patients who had never responded to IFX [16].…”

Section: Introductionmentioning

confidence: 99%

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

et al. 2010

View full text Add to dashboard Cite

Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with moderate-to-severe Crohn’s disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. Aim: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD. Methods: We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI of ≤4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. Results: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4–6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smoking status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4–6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. Conclusion: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long-term effectiveness.

show abstract

“…136 In the PRECiSE 2 study, of the one-third of patients who had previously failed infliximab treatment, 44% responded to certolizumab. In the whole study population the response rate to certolizumab was higher in patients who were infliximab-naive (69%).…”

Section: Increase Dose or Reduce Dose Intervalmentioning

confidence: 99%

Practical application of anti-TNF therapy for luminal Crohnʼs disease

Kamm

Cruz

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Anti-tumor necrosis factor (TNF) therapy to treat inflammatory bowel disease has been available for more than a decade. Although extensive data on the outcome of anti-TNF therapy from individual clinical trials and patient cohorts are available, integrated guidance on the best use of such therapy to achieve optimal clinical outcomes when managing patients with luminal Crohn's disease is lacking. This review combines published data to establish practical strategies for anti-TNF therapy with respect to effective and safe timing of introduction, use of concurrent immunosuppressive therapy, dose escalation, managing relapse, changing drugs, pregnancy and breast feeding, and stopping drug treatment.

show abstract

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3‐year single‐centre experience

Abstract: SUMMARY BackgroundAdalimumab is effective in inducing clinical remission in patients with Crohn's disease who lost response or became intolerant to infliximab.

Cited by 36 publications

References 20 publications

How do patients with inflammatory bowel disease want their biological therapy administered?

How do patients with inflammatory bowel disease want their biological therapy administered?

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

Practical application of anti-TNF therapy for luminal Crohnʼs disease

Contact Info

Product

Resources

About